Bolt Biotherapeutics Inc (NAS:BOLT)
$ 0.626 -0.0039 (-0.62%) Market Cap: 23.96 Mil Enterprise Value: -11.66 Mil PE Ratio: 0 PB Ratio: 0.33 GF Score: 40/100

Bolt Biotherapeutics Inc at Stifel Healthcare Conference Transcript

Nov 16, 2022 / 06:15PM GMT
Release Date Price: $1.37 (+7.03%)
Stephen Willey
Stifel Financial Corp. - Analyst

I'm Stephen Willey, one of the senior biotech analysts here at Stifel, and glad to have with us from Bolt Biotherapeutics, Chief Financial Officer, Willie Quinn. Also in attendance from Bolt is Karen Bergman, who heads up the Corporate Communications and IR effort.

Willie is going to give us a presentation and overview of the company. (Operator Instructions) Willie, I really appreciate the time here, and looking forward to the presentation.

Willie Quinn
Bolt Biotherapeutics, Inc. - CFO

Thank you, Steve. So Bolt Biotherapeutics -- I am going to be making a few forward-looking statements today. Please refer to our filings.

It's a very exciting time at Bolt right now. We have a number of pipeline programs, including one that's in a dose escalation trial right now. And it's a novel mechanism, an immune-stimulating antibody conjugate, and really provides proof of principle for our broader platform. We have a number of collaborations, including one with Genmab, one with Innovent. Generally, the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot